T. HERVEY and J. McHALE, Health Law and the European Union, Cambridge University Press, Cambridge, 2004, Paperback, 469 pp.,  35

Abstract Coronavirus Disease 2019 (COVID-19) is the most dramatic pandemic of the new millennium, and extraordinary measures concerning with health, law and policy are required around the world. One of these is without doubts the “green pass”, officially known in the European Union (EU) as EU Digital COVID Certificate (EUDCC). Initially conceived as a tool for overcoming the lockdown restrictions, it has unexpectedly turned into a means of discrimination between pass holders and non-holders, thus increasing social tension at the expense of solidarity and brotherhood. Here, we analyze in depth the dark sides of the “green pass” in the light of the European and international legislation and of the ongoing pandemic scenario.

Download Full-text

The Politics of Sexual Harassment: A Comparative Study of the United States, the European Union, and Germany. By Kathrin S. Zippel. Cambridge: Cambridge University Press, 2006. xviii, 255 pp. Hardcover $80.00; paper $34.99.

Politics & Gender ◽

10.1017/s1743923x07000153 ◽

2007 ◽

Vol 3 (03) ◽

Author(s):

Louise K. Davidson-Schmich

Keyword(s):

United States ◽

European Union ◽

Sexual Harassment ◽

Comparative Study ◽

The United States ◽

The European Union ◽

Cambridge University

Download Full-text

Daphne Spain and Suzanne M. Bianchi, Balancing Act: Motherhood, Marriage and Employment Among American Women, Russell Sage Foundation, New York, 1996, 240 pp., $39.95 hard, $16.95 paper. Maria Dolors Garcia-Ramon and Janice Monks (eds.), Women of the European Union: the Politics of Work and Daily Life, Routledge, London and New York, 1996, 288 pp., £14.99 paper. Diane Sainsbury, Gender, Equality and Welfare States, Cambridge University Press, Cambridge, 1996, 258 pp., £40.00 hard, £14.95 paper.

Journal of Social Policy ◽

10.1017/s0047279497245228 ◽

1998 ◽

Vol 27 (1) ◽

pp. 123-149

Author(s):

GILLIAN PASCALL

Keyword(s):

New York ◽

European Union ◽

Gender Equality ◽

Daily Life ◽

Welfare States ◽

Russell Sage Foundation ◽

The European Union ◽

Cambridge University ◽

American Women

Download Full-text

Excessive pricing in the pharmaceutical industry: adding another string to the bow of EU competition law

Health Economics Policy and Law ◽

10.1017/s1744133120000109 ◽

2020 ◽

pp. 1-12

Author(s):

Diletta Danieli

Keyword(s):

European Union ◽

Pharmaceutical Industry ◽

Competition Law ◽

Pharmaceutical Companies ◽

Health Law ◽

The European Union ◽

The United Kingdom ◽

Eu Competition Law ◽

Policy Objectives ◽

The Eu

Abstract The paper addresses the issue of excessive price abuse under Article 102(a) of the Treaty on the Functioning of the European Union (TFEU), by drawing inspiration from a recent stream of cases (developed first at the national and then at the EU level) involving pharmaceutical companies marketing off-patent drugs. In particular, the two ‘most advanced’ cases are analysed: Aspen in Italy and Pfizer/Flynn in the United Kingdom. This new-found attention towards exploitative practices in the form of excessive and unfair pricing by dominant undertakings that have traditionally been subject to a cautious antitrust scrutiny seems worth exploring for a number of reasons, as illustrated in the paper. Ultimately, it is argued that this further ‘interference’ of competition law into the realms of regulation may be actually justified, albeit subject to precise conditions for enforcement, and may pursue policy objectives in the wider context of EU health law.

Download Full-text